参考文献/References:
[1] MICHAELS E,WORTHINGTON R O,RUSIECKI J.Breast cancer:risk assessment,screening,and primary prevention[J].Med Clin North Am,2023,107(2):271-284.
[2] 柴效科,卫翀羿,程晓成,等.激素受体阳性/人类表皮生长因子受体2阴性乳腺癌靶向治疗研究进展[J].〖KG-\*4〗新乡医学院学报,2023,40(5):490-496.
CHAI X K,WEI C Y,CHENG X C,et al.Research progress on targeted therapy of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer[J].J Xinxiang Med Univ,2023,40(5):490-496.
[3] HARBECK N.〖KG-\*8〗Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer[J].Breast,2022,62(Suppl 1):S12-S16.
[4] ALDRICH J,CANNING M,BHAVE M.Monitoring of triple negative breast cancer after neoadjuvant chemotherapy[J].〖KG-\*8〗Clin Breast Cancer,2023,23(8):832-834.
[5] FENG W,HE Y,XU J,et al.A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer[J].Anticancer Drugs,2022,33(1):e52-e60.
[6] GROOT S D,LUGTENBERG R T,COHEN D,et al.Fasting mimic-king diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial[J].Nat Commun,2020,11(1)〖KG-\*8〗:3083.
[7] GIAMMARILE F,VIDAL-SICART S,PAEZ D,et al.Sentinel lymph node
Methods in breast cancer[J].Semin Nucl Med,2022,52(5):551-560.
[8] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].〖KG-\*8〗中国癌症杂志,2017,27(9):695-759.
BREAST CANCER PROFESSIONAL COMMITTEE OF CHINESE ANTI-CANCER ASSOCIATION.Guidelines and specifications for diagnosis and treatment of breast cancer of China Anti-Cancer Association (2017 edition)[J].China Oncol,2017,27(9):695-759.
[9] FISHER C S.Neoadjuvant chemotherapy for breast cancer:the ultimate “spy”[J].Ann Surg Oncol,2022,29(11):6508-6510.
[10] 崔茹婷,吕志栋,姚瑶,等.钙周期素结合蛋白对乳癌新辅助化疗效果的预测价值[J].青岛大学学报(医学版),2022,58(5):714-719.
CUI R T,LV Z D,YAO Y,et al.Value of calcyclin-binding protein in predicting the efficacy of neoadjuvant chemotherapy for breast cancer[J].J Qingdao Univ Med Sci,2022,58(5):714-719.
[11] KATSURA C,OGUNMWONYI I,KANKAM H K,et al.Breast cancer:presentation,investigation and management[J].Br J Hosp 〖HJ1.49mm〗Med (Lond),2022,83(2):1-7.
[12] 蔡凌翼,陈涛,张晓琳,等.基于基因组学视角的乳腺癌化疗耐药机制研究进展[J].中华全科医学,2023,21(12):2005-2008,2073.
CAI L Y,CHEN T,ZHANG X L,et al.Advances in the study of chemotherapy resistance mechanisms in breast cancer based on genomics perspective[J].Chin J Gen Pract,2023,21(12):2005-2008,2073.
[13] HAQUE W,VERMA V,SCHWARTZ M R,et al.Neoadjuvant chemotherapy for metaplastic breast cancer:response rates,management,and outcomes[J].Clin Breast Cancer,2022,22(5):e691-e699.
[14] 杨柳,张明坤,季福庆,等.HER-2阳性乳腺癌新辅助化疗疗效影响因素分析及相关预后模型的构建[J].现代肿瘤医学,2023,31(11):2037-2041.
YANG L,ZHANG M K,JI F Q,et al.The analysis of the factors affecting pathological complete response of HER-2 positive breast cancer patients after neoadjuvant chemotherapy and the construction of related model[J].〖KG-\*8〗J Mod Oncol,2023,31(11):2037-2041.
[15] 李芷凡,刘欣然,王子圆,等.ADC最大值联合激素受体及人表皮生长因子受体2预测乳腺癌新辅助化疗疗效[J].磁共振成像,2023,14(10):71-77.
LI Z F,LIU X R,〖KG-\*8〗WANG Z Y,et al.Predicting the efficacy of neoadjuvant chemotherapy for breast cancer by combining hormone receptor and human epidermal growth factor receptor 2 with ADC maximum[J].Chin J Magn Reson Imag,2023,14(10):71-77.
[16] 苏天放,范明,厉力华.基于纵向时间影像动态增强模式分析的乳腺癌新辅助化疗疗效预测[J].中国生物医学工程学报,2023,42(2):139-147.
SU T F,FAN M,LI L H.〖KG-\*8〗Prediction of breast cancer neoadjuvant chemotherapy based on dynamic enhanced mode analysis of longitudinal time images[J].Chin J Biomed Eng,2023,42(2):139-147.
[17] SINGAPORE CANCER NETWORK BREAST CANCER WORKGROUP.Singapore cancer network (SCAN) guidelines for bisphosphonate use in the adjuvant breast cancer setting[J].Ann Acad Med Singap,2015,44(10):368-378.
[18] TYAGI N K,DHESY-THIND S.Clinical practice guidelines in breast cancer[J].Curr Oncol,2018,25(Suppl 1):S151-S160.
[19] 樊庆达,丛斌斌,陈玉光,等.临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展[J].〖KG-\*8〗中国癌症杂志,2023,33(2):174-180.
FAN Q D,CONG B B,CHEN Y G,et al.Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients[J].China Oncol,2023,33(2):174-180.
[20] BOUGHEY J C,SUMAN V J,MITTENDORF E A,et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer:the ACOSOG Z1071 (Alliance) clinical trial[J].JAMA,2013,310(14):1455-1461.
[21] VAN DER NOORDAA M,VAN DUIJNHOVEN F,CUIJPERS V,et al.Omitting sentinel lymph node biopsy after neoadjuvant systemic therapy in selected breast cancer patients with clinical node-negative disease[J].Eur J Cancer,2018,92:S14.
[22] BLUM MURPHY M,XIAO L,PATEL V R,et al.Pathological complete response in patients with esophageal cancer after the trimodality approach:the association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience[J].Cancer,2017,123(21):4106-4113.
相似文献/References:
[1]路 娜,古吉敏,闵志波.肿瘤间质比在三阴性乳腺癌患者预后评估中的价值[J].新乡医学院学报,2017,34(12):1089.[doi:10.7683/xxyxyxb.2017.12.011]
LU Na,GU Ji-min,MIN Zhi-bo.Value of tumor-stroma ratio in evaluating the prognosis of patients with triple-negative breast cancer[J].Journal of Xinxiang Medical University,2017,34(4):1089.[doi:10.7683/xxyxyxb.2017.12.011]
[2]刘 明,郭 满,张 浩,等.血管生成拟态及骨桥蛋白和基质金属蛋白酶2在三阴性乳腺癌组织中的表达及意义[J].新乡医学院学报,2019,36(4):345.[doi:10.7683/xxyxyxb.2019.04.011]
LIU Ming,GUO Man,ZHANG Hao,et al.Expression and significance of vasculogenic mimicry,osteopontin and matrix metalloproteinase-2 in triple-negative breast cancer[J].Journal of Xinxiang Medical University,2019,36(4):345.[doi:10.7683/xxyxyxb.2019.04.011]
[3]郭 满,翟晓建,张 浩,等.p38蛋白激酶信号通路对骨桥蛋白介导的三阴性乳腺癌细胞自噬、凋亡活性的影响[J].新乡医学院学报,2018,35(12):1058.[doi:10.7683/xxyxyxb.2018.12.004]
GUO Man,ZHAI Xiao-jian,ZHANG Hao,et al.Effect of p38 mitogen-activated protein kinase signaling pathway on autophagy and apoptosis activity of triple negative breast cancer cell mediated by osteopontin[J].Journal of Xinxiang Medical University,2018,35(4):1058.[doi:10.7683/xxyxyxb.2018.12.004]
[4]刘德总,杨颖涛.乳腺癌辅助治疗现状与展望[J].新乡医学院学报,2021,38(8):781.[doi:10.7683/xxyxyxb.2021.08.017]
[5]郭彬彬,郭 满,刘 明,等.扭曲蛋白、波形蛋白、血管生成拟态在三阴性乳腺癌组织中的表达及临床意义[J].新乡医学院学报,2021,38(5):436.[doi:10.7683/xxyxyxb.2021.05.008]
GUO Binbin,GUO Man,LIU Ming,et al.Expression of Twist,vimentin and vasculogenic mimicry in triple-negative breast cancer tissues and its clinical significance[J].Journal of Xinxiang Medical University,2021,38(4):436.[doi:10.7683/xxyxyxb.2021.05.008]
[6]付朝红,刘丹娜,段方方,等.晚期三阴性乳腺癌核苷酸切除修复交叉互补基因1表达与化学治疗效果的关系[J].新乡医学院学报,2017,34(10):904.[doi:10.7683/xxyxyxb.2017.10.010]
FU Chao-hong,LIU Dan-na,DUAN Fang-fang,et al.Relationship between excision repair cross complementing gene 1 expression and chemotherapeutic efficacy in patients with advanced triple-negative breast cancer[J].Journal of Xinxiang Medical University,2017,34(4):904.[doi:10.7683/xxyxyxb.2017.10.010]
[7]朱方园,邵营波,陈 琦,等.长链非编码RNA前列腺癌相关转录本7对三阴性乳腺癌MDA-MB-436细胞增殖、迁移及侵袭的影响[J].新乡医学院学报,2022,39(8):701.[doi:10.7683/xxyxyxb.2022.08.001]
ZHU Fangyuan,SHAO Yingbo,CHEN Qi,et al.Effect of long non-coding RNA prostate cancer associated transcript 7 on proliferation,migration and invasion of triple-negative breast cancer MDA-MB-436 cells[J].Journal of Xinxiang Medical University,2022,39(4):701.[doi:10.7683/xxyxyxb.2022.08.001]